ARG-007
Acute ischemic stroke, traumatic brain injury, hypoxic‑ischemic encephalopathy
Phase 2Active
Key Facts
Indication
Acute ischemic stroke, traumatic brain injury, hypoxic‑ischemic encephalopathy
Phase
Phase 2
Status
Active
Company
About Argenica Therapeutics
Australian‑stage biotech delivering a first‑responder neuroprotective therapy for stroke and acute brain injury.
View full company profile